3
Total investments
1
Early stage
0
Mid stage
0
Late stage
13y
Years active
Portfolio
1 investments · sorted by recency
All investments
Early stage
Mid stage
Late stage
Board Member
2014
We are a late stage biopharmaceutical company focused on the development and commercialization of serlopitant for the treatment of pruritus, or itch, associated with various conditions. We believe that serlopitant, a highly selective small molecule inhibitor of the neurokinin 1 receptor, or NK1R, given as a once daily, oral tablet, has the potential to significantly alleviate pruritus associated with various conditions.
Experience · 4 entries
All (4)
Investments (3)
Board (3)
2014
S
Starfish Asset Fund
Board Member
2014
Board Member
2014
We are a late stage biopharmaceutical company focused on the development and commercialization of serlopitant for the treatment of pruritus, or itch, associated with various conditions. We believe that serlopitant, a highly selective small molecule inhibitor of the neurokinin 1 receptor, or NK1R, given as a once daily, oral tablet, has the potential to significantly alleviate pruritus associated with various conditions.
2013
M
Menlo Therapeutics Inc. (NASDAQ: MNLO)
Board Member
Oct 2013
1999
Investment activity
2013–2014 · 3 investments
Recent (last 2 years)Earlier
Investor lists
Lists that match Ted's portfolio
- Manufacturing investors in United States2,849 investors
- Startup investors in United States6,245 investors